Literature DB >> 21517927

High-risk antimicrobial prescriptions among ambulatory patients on warfarin.

M A Lane1, S T Devine, J R McDonald.   

Abstract

WHAT IS KNOWN AND
OBJECTIVE: Warfarin is a potent anticoagulant with many drug-drug interactions, including antimicrobials. There is limited data on the frequency of prescription of high-risk antimicrobials to patients on warfarin. To examine the frequency of prescriptions for potentially interacting antimicrobials in ambulatory patients on warfarin and the impact of warfarin on the prescription of high-risk antimicrobials.
METHODS: A retrospective cohort study of patients with pharmacy benefits who had ≥1 claim for an oral antimicrobial between 1 January 2008 and 31 December 2008 was conducted, utilizing a pharmacy benefits database. Demographic data including age, gender, chronic disease score (CDS) and geographic location were determined. Warfarin users were defined as any patient with ≥1 claim for warfarin during the follow-up period. Antimicrobials considered high risk for potential interaction with warfarin based on existing literature included trimethoprim/sulfamethoxazole, levofloxacin, ciprofloxacin, metronidazole and fluconazole. Multivariate analysis was used to determine the impact of warfarin use and other factors on high-risk antimicrobial prescription. RESULTS AND DISCUSSION: A total of 4,568,150 patients with ≥1 claim for antimicrobials during 2008 were analysed. Of them, 110,192 (2·4%) also had one or more claims for warfarin. Among all antimicrobial prescriptions in warfarin users, 42·6% were for high-risk antimicrobials. The mean number of antimicrobial prescriptions was 3·0 in warfarin users versus 2·4 in warfarin non-users (P-value <0·001). After adjusting for age, gender, CDS and geography, the odds of exposure to high-risk antimicrobials was 42% lower (OR 0·58; P-value <0·001) in warfarin users compared with warfarin non-users. WHAT IS NEW AND
CONCLUSIONS: A high percentage (42·6%) of antimicrobial prescriptions among warfarin users were for high-risk antimicrobials that carry excess bleeding risk. Although clinicians were somewhat less likely to prescribe high-risk antimicrobials to warfarin users compared with non-users, the incidence of co-prescription remains high.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21517927      PMCID: PMC3144980          DOI: 10.1111/j.1365-2710.2011.01270.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  22 in total

Review 1.  Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.

Authors:  J Hirsh; J Dalen; D R Anderson; L Poller; H Bussey; J Ansell; D Deykin
Journal:  Chest       Date:  2001-01       Impact factor: 9.410

2.  The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation.

Authors:  Daniel E Singer; Robert A Hughes; Daryl R Gress; Mary A Sheehan; Lynn B Oertel; Sue Ward Maraventano; Dyan Ryan Blewett; Bernard Rosner; J Philip Kistler
Journal:  N Engl J Med       Date:  1990-11-29       Impact factor: 91.245

Review 3.  Clinical practice. Care of patients receiving long-term anticoagulant therapy.

Authors:  Sam Schulman
Journal:  N Engl J Med       Date:  2003-08-14       Impact factor: 91.245

4.  A chronic disease score from automated pharmacy data.

Authors:  M Von Korff; E H Wagner; K Saunders
Journal:  J Clin Epidemiol       Date:  1992-02       Impact factor: 6.437

5.  The stereoselective interaction of warfarin and metronidazole in man.

Authors:  R A O'Reilly
Journal:  N Engl J Med       Date:  1976-08-12       Impact factor: 91.245

6.  Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants.

Authors:  Loes E Visser; Fernie J A Penning-van Bees; A A Harrie Kasbergen; Peter A G M De Smet; Arnold G Vulto; Albert Hofman; Bruno H Ch Stricker
Journal:  Thromb Haemost       Date:  2002-11       Impact factor: 5.249

7.  Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.

Authors:  P Petersen; G Boysen; J Godtfredsen; E D Andersen; B Andersen
Journal:  Lancet       Date:  1989-01-28       Impact factor: 79.321

8.  Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators.

Authors:  M D Ezekowitz; S L Bridgers; K E James; N H Carliner; C L Colling; C C Gornick; H Krause-Steinrauf; J F Kurtzke; S M Nazarian; M J Radford
Journal:  N Engl J Med       Date:  1992-11-12       Impact factor: 91.245

9.  Stroke Prevention in Atrial Fibrillation Study. Final results.

Authors: 
Journal:  Circulation       Date:  1991-08       Impact factor: 29.690

10.  Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis.

Authors:  Lori-Ann Linkins; Peter T Choi; James D Douketis
Journal:  Ann Intern Med       Date:  2003-12-02       Impact factor: 25.391

View more
  5 in total

1.  Serious bleeding events due to warfarin and antibiotic co-prescription in a cohort of veterans.

Authors:  Michael A Lane; Angelique Zeringue; Jay R McDonald
Journal:  Am J Med       Date:  2014-03-19       Impact factor: 4.965

Review 2.  Addressing phenoconversion: the Achilles' heel of personalized medicine.

Authors:  Rashmi R Shah; Robert L Smith
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

Review 3.  Ovarian stimulation and embryo banking for fertility preservation in a woman with severe mixed connective tissue disease: Is it safe?

Authors:  Vasileios D Sioulas; Clarisa R Gracia
Journal:  J Assist Reprod Genet       Date:  2011-12-29       Impact factor: 3.412

4.  Characteristics of patients with thromboembolic disorders on warfarin therapy in resource limited settings.

Authors:  Zipporah Kamuren; Gabriel Kigen; Alfred Keter; Alice Maritim
Journal:  BMC Health Serv Res       Date:  2018-09-19       Impact factor: 2.655

5.  Adherence to guidelines for avoiding drug interactions associated with warfarin--a Nationwide Swedish Register Study.

Authors:  Jonatan D Lindh; Marine L Andersson; Buster Mannheimer
Journal:  PLoS One       Date:  2014-05-15       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.